$135.44
Today
as of Jul 22, 16:53 ET
Last 30 days
Recent Press Releases & News
Protagonist Therapeutics Reports Granting of Inducement Awards
PTGX: Lowering target price to $138.00
Protagonist Therapeutics (PTGX) Stock Still Looks Stretched After FDA Priority Review
Overview
52-week range
$49
$108
100% of range
Avg surprise (last 3)
+55.3%
Avg reaction (last 2)
-2.7%
0% positive
Latest IV / EM
70%
EM ±16.0% · $135 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 5, 2026 | Mar/2026 | $0.05 | $-0.65 | +107.7% | +126.3% | -0.3% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.62 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $-0.55 | $-0.53 | -3.8% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $-0.19 | $-0.50 | +62.0% | — | -5.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.54 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.50 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $3.26 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.58 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.68 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 5, 2026 | Jun/2026 | OTHER | $2.11 | -$0.55 | +483.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-4M | — | $-46M | $-42M | $-19M | — | $-41M | $-39M |
| Net income | $4M | — | $-39M | $-35M | $-12M | — | $-33M | $-31M |
| EPS (diluted) | $0.05 | — | $-0.62 | $-0.55 | $-0.19 | — | $-0.54 | $-0.50 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $194M | $128M | $114M | $169M | $140M | $97M | $131M | $356M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $613M | $578M | $586M | $603M | $606M | $592M | $477M | $571M |
| Total assets | $697M | $668M | $702M | $718M | $742M | $745M | $604M | $615M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $42M | $53M | $56M | $50M | $53M | $69M | $72M | $73M |
| Total equity | $655M | $615M | $645M | $668M | $689M | $675M | $532M | $541M |